MacroGenics, Inc. (MGNX)
Latest news, insights and market data
Market Data
AI Insights
MacroGenics announced positive interim results for MGC026, showing a 27% overall response rate in heavily pretreated SCCHN patients. This suggests potential effectiveness for a challenging patient group and sets the stage for a front-line combination study with pembrolizumab. The manageable safety profile adds to the optimism around MGC026's future in cancer treatment.
Latest News
| Title | Published |
|---|---|
Top US Stock Gainers and Losers in Today's Session Top US market movers today: CLRO gained 76.04% among gainers, while AARD fell 61.52% among losers in the session. | 1 day ago |
Today's U.S. Session Top Movers: Small-Cap Gainers and Losers Today's U.S. session top movers feature small-cap gainers led by CLRO, YMAT and GPUS, while AARD, SHFS and TANH lead the decliners. | 1 day ago |
Gap-Up and Gap-Down Stocks: October 23, 2026 Session October 23, 2026 gap movers include YMAT up 55.61% and AARD down 44.81%, with notable gap-up and gap-down stocks across the session. | 1 day ago |
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN | 1 day ago |
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN patientsMGC026 demonstrated manageable safety and tolerability profile with no treatment-related discontinuations in SCCHN patientsPlan to initiate front-line SCCHN cohort evaluating MGC026 in combination with pembrolizumab ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (N | 1 day ago |
MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN | 2 days ago |
MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors | 9 days ago |
Top US Stock Gainers and Losers in Today's Session
Top US market movers today: CLRO gained 76.04% among gainers, while AARD fell 61.52% among losers in the session.
Today's U.S. Session Top Movers: Small-Cap Gainers and Losers
Today's U.S. session top movers feature small-cap gainers led by CLRO, YMAT and GPUS, while AARD, SHFS and TANH lead the decliners.
Gap-Up and Gap-Down Stocks: October 23, 2026 Session
October 23, 2026 gap movers include YMAT up 55.61% and AARD down 44.81%, with notable gap-up and gap-down stocks across the session.
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN patientsMGC026 demonstrated manageable safety and tolerability profile with no treatment-related discontinuations in SCCHN patientsPlan to initiate front-line SCCHN cohort evaluating MGC026 in combination with pembrolizumab ROCKVILLE, MD, Oct. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (N
MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial
Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated SCCHN
MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors
MacroGenics Says First Patient Dosed in Phase 1 Study of MGC030 for Advanced Solid Tumors